About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 143273, 9 pages
http://dx.doi.org/10.1155/2013/143273
Clinical Study

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients

1Medical Oncology, S. Salvatore Hospital, University of L'Aquila, 67100 L'Aquila, Italy
2Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L'Aquila, Italy
3Radiology, S. Salvatore Hospital, 67100 L'Aquila, Italy
4Hepatobiliar-Pancreatic Surgery, S. Salvatore Hospital, 67100 L'Aquila, Italy

Received 26 June 2013; Revised 31 August 2013; Accepted 13 September 2013

Academic Editor: Hidekazu Kuramochi

Copyright © 2013 Gemma Bruera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Bruera, A. Santomaggio, K. Cannita et al., ““Poker” association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study,” BMC Cancer, vol. 10, article 567, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Bruera and E. Ricevuto, “Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845–52,” Expert Opinion on Bioogical Theraphy, vol. 11, no. 6, pp. 821–824, 2011. View at Publisher · View at Google Scholar
  3. G. Bruera, K. Cannita, F. Giuliante et al., “Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab,” Clinical Colorectal Cancer, vol. 11, no. 2, pp. 119–126, 2012.
  4. C. Ficorella, G. Bruera, K. Cannita et al., “Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice,” Clinical Colorectal Cancer, vol. 11, no. 4, pp. 229–237, 2012.
  5. G. Bruera, K. Cannita, D. Di Giacomo et al., “Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease,” BMC Medicine, vol. 10, no. 1, article 135, 2012.
  6. G. Bruera, K. Cannita, A. V. Giordano, R. Vicentini, C. Ficorella, and E. Ricevuto, “Differential prognosis of metastatic colorectal cancer patients post-progression to first line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second line treatment and KRAS genotype,” International Journal of Oncology. In press.
  7. G. Masi, E. Vasile, F. Loupakis et al., “Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis,” Journal of the National Cancer Institute, vol. 103, no. 1, pp. 21–30, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. H. J. Schmoll, E. Van Cutsem, A. Stein et al., “ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making,” Annals of Oncology, vol. 23, pp. 2479–2516, 2012.
  9. A. G. Pallis, D. Papamichael, R. Audisio et al., “EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients,” Cancer Treatment Reviews, vol. 36, no. 1, pp. 83–90, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Papamichael, R. Audisio, J.-C. Horiot et al., “Treatment of the elderly colorectal cancer patient: SIOG expert recommendations,” Annals of Oncology, vol. 20, no. 1, pp. 5–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. R. A. Audisio and D. Papamichael, “Treatment of colorectal cancer in older patients,” Nature Reviews Gastroenterology & Hepatology, vol. 9, no. 12, pp. 716–725, 2012.
  12. M. Extermann, J. Overcash, G. H. Lyman, J. Parr, and L. Balducci, “Comorbidity and functional status are independent in older cancer patients,” Journal of Clinical Oncology, vol. 16, no. 4, pp. 1582–1587, 1998. View at Scopus
  13. G. Folprecht, D. Cunningham, P. Ross et al., “Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials,” Annals of Oncology, vol. 15, no. 9, pp. 1330–1338, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. R. A. Popescu, A. Norman, P. J. Ross, B. Parikh, and D. Cunningham, “Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older,” Journal of Clinical Oncology, vol. 17, no. 8, pp. 2412–2418, 1999. View at Scopus
  15. S. Chiara, M. T. Nobile, M. Vincenti et al., “Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy,” Cancer Chemotherapy and Pharmacology, vol. 42, no. 4, pp. 336–340, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Folprecht, M. T. Seymour, L. Saltz et al., “Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials,” Journal of Clinical Oncology, vol. 26, no. 9, pp. 1443–1451, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Mitry, J.-Y. Douillard, E. Van Cutsem et al., “Predictive factors of survival in patients with advanced colorectal cancer: an indiviual data analysis of 602 patients included in irinotecan phase III trials,” Annals of Oncology, vol. 15, no. 7, pp. 1013–1017, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. R. M. Goldberg, I. Tabah-Fisch, H. Bleiberg et al., “Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer,” Journal of Clinical Oncology, vol. 24, no. 25, pp. 4085–4091, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Figer, N. Perez-Staub, E. Carola et al., “FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study,” Cancer, vol. 110, no. 12, pp. 2666–2671, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. T. Seymour, L. C. Thompson, H. S. Wasan et al., “Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial,” The Lancet, vol. 377, no. 9779, pp. 1749–1759, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. F. F. Kabbinavar, H. I. Hurwitz, J. Yi, S. Sarkar, and O. Rosen, “Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials,” Journal of Clinical Oncology, vol. 27, no. 2, pp. 199–205, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Cassidy, L. B. Saltz, B. J. Giantonio, F. F. Kabbinavar, H. I. Hurwitz, and U.-P. Rohr, “Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies,” Journal of Cancer Research and Clinical Oncology, vol. 136, no. 5, pp. 737–743, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. F. Kozloff, J. Berlin, P. J. Flynn et al., “Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study,” Oncology, vol. 78, no. 5-6, pp. 329–339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Van Cutsem, F. Rivera, S. Berry et al., “Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study,” Annals of Oncology, vol. 20, no. 11, pp. 1842–1847, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. Meyerhardt, N. Jackson McCleary, D. Niedzwiecki et al., “Impact of age and comorbidities on treatment effect, tolerance, and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB, 80203,” Journal of Clinical Oncology, vol. 27, 15s (supplement, abstr 4038), 2009.
  27. J.-Y. Douillard, S. Siena, J. Cassidy et al., “Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) Versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study,” Journal of Clinical Oncology, vol. 28, no. 31, pp. 4697–4705, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Souglakos, N. Androulakis, K. Syrigos et al., “FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG),” British Journal of Cancer, vol. 94, no. 6, pp. 798–805, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Vamvakas, A. Athanasiadis, A. Karampeazis et al., “Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG),” Critical Reviews in Oncology/Hematology, vol. 76, no. 1, pp. 61–70, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Ficorella, E. Ricevuto, M. F. Morelli et al., “Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: a dose-finding study,” Oncology Reports, vol. 15, no. 5, pp. 1345–1350, 2006. View at Scopus
  31. M. F. Morelli, A. Santomaggio, E. Ricevuto et al., “Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study,” Oncology Reports, vol. 23, no. 6, pp. 1635–1640, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Di Fiore, F. Blanchard, F. Charbonnier et al., “Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy,” British Journal of Cancer, vol. 96, no. 8, pp. 1166–1169, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Lamy, F. Blanchard, F. Le Pessot et al., “Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls,” Modern Pathology, vol. 24, no. 8, pp. 1090–1100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Mantel, “Chi-square tests with one degree of freedom: extensions of the Mendel-Haenszel procedure,” Journal of the American Statistical Association, vol. 58, pp. 690–700, 1963.
  35. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Scopus
  36. E. L. Kaplan and P. Meier, “Nonparametric estimation of incomplete observations,” Journal of the American Statistical Association, vol. 53, pp. 457–481, 1958.
  37. R. Peto and J. Peto, “Asymptomatically efficient rank invariant test procedures,” Journal of the Royal Statistical Society A, vol. 135, pp. 185–206, 1972.
  38. G. Masi, F. Loupakis, L. Salvatore et al., “Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial,” The Lancet Oncology, vol. 11, no. 9, pp. 845–852, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Garufi, A. Torsello, S. Tumolo et al., “Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial,” British Journal of Cancer, vol. 103, no. 10, pp. 1542–1547, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. D. J. Sargent, C. H. Köhne, H. K. Sanoff et al., “Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 1948–1955, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Adam, A. Frilling, D. Elias et al., “Liver resection of colorectal metastases in elderly patients,” British Journal of Surgery, vol. 97, no. 3, pp. 366–376, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Figueras, E. Ramos, S. López-Ben et al., “Surgical treatment of liver metastases from colorectal carcinoma in elderly patients. When is it worthwhile?” Clinical and Translational Oncology, vol. 9, no. 6, pp. 392–400, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. F. A. Scappaticci, J. R. Skillings, S. N. Holden et al., “Arterial thromboembolic events and patients with metastatic carcinoma treated with chemotherapy and bevacizumab,” Journal of the National Cancer Institute, vol. 99, pp. 1232–1239, 2007. View at Publisher · View at Google Scholar · View at Scopus